Glycobiology · 2022 · 26 citations · 28 references
Life SciencesBiochemistryMolecular BiologyCell SignalingCellular ImmunologyGlycobiologyB Cell BiologyCell-surface GlycansGlycan BiosynthesisGlycan StructureGlycosylation PathwaysImmunoglobulin FunctionAntibody Glycosylation ControlAntibody Glycosylation EffectsImmunoglobulin Glycosylation
The glycosylation of immunoglobulin G (IgG) has attracted increased attention due to the impact of N-glycan modifications at N297 on IgG function, acting primarily through modulation of Fc domain conformation and Fcγ receptor-binding affinities and signaling. However, the mechanisms regulating IgG glycosylation and especially α2,6-sialylation of its N-glycan remain poorly understood. We observed previously that IgG is normally sialylated in mice with B cells lacking the sialyltransferase ST6Gal1. This supported the hypothesis that IgG may be sialylated outside of B cells, perhaps through the action of hepatocyte-released plasma ST6Gal1. Here, we demonstrate that this model is incorrect. Animals lacking hepatocyte expressed ST6Gal1 retain normal IgG α2,6-sialylation despite the lack of detectable ST6Gal1 in plasma. Moreover, we confirmed that B cells were not a redundant source of IgG sialylation. Thus, while α2,6-sialylation is lacking in IgG from mice with germline ablation of ST6Gal1, IgG α2,6-sialylation is normal in mice lacking ST6Gal1 in either hepatocytes or B cells. These results indicate that IgG α2,6-sialylation arises after release from a B cell but is not dependent on plasma-localized ST6Gal1 activity.
28
Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway
Robert M. Anthony, Toshihiko Kobayashi, Fredrik Wermeling et al. · Nature · 2011 · 617 citations · Full text
Fleur E. van de Geijn, Manfred Wuhrer, Maurice H. J. Selman et al. · Arthritis Research & Therapy · 2009 · 270 citations · Full text